Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-Center, Observational Study to Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus

NCT05926414 is registered in ClinicalTrials.gov with Daewoong Pharmaceutical Co. LTD. as lead sponsor.

NCT NCT05926414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05926414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-Center, Observational Study to Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus
Lead sponsor
Daewoong Pharmaceutical Co. LTD.
Phase
Observational
Overall status
Active, not recruiting
Start date
September 21, 2023
Completion date
December 31, 2025
Enrollment
15,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2